Gossamer Bio Stock Today
| GOSS Stock | USD 0.70 0.03 4.11% |
Performance0 of 100
| Odds Of DistressOver 83
|
Gossamer Bio is selling for under 0.7 as of the 4th of December 2024; that is 4.11 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.69. Gossamer Bio has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Gossamer Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of November 2024 and ending today, the 4th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of February 2019 | Category Healthcare | Classification Health Care |
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California. The company has 226.6 M outstanding shares of which 6.53 M shares are currently shorted by private and institutional investors with about 7.99 trading days to cover. More on Gossamer Bio
Moving together with Gossamer Stock
Moving against Gossamer Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Gossamer Stock Highlights
| Chairman | Faheem Hasnain | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsGossamer Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Gossamer Bio's financial leverage. It provides some insight into what part of Gossamer Bio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Gossamer Bio (GOSS) is traded on NASDAQ Exchange in USA. It is located in 3013 Science Park Road, San Diego, CA, United States, 92121 and employs 135 people. Gossamer Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 158.62 M. Gossamer Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 226.6 M outstanding shares of which 6.53 M shares are currently shorted by private and institutional investors with about 7.99 trading days to cover.
Gossamer Bio currently holds about 304.38 M in cash with (159.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Gossamer Bio Probability Of Bankruptcy
Ownership AllocationGossamer Bio has a total of 226.6 Million outstanding shares. The majority of Gossamer Bio outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Gossamer Bio to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Gossamer Bio. Please pay attention to any change in the institutional holdings of Gossamer Bio as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Gossamer Ownership Details
Gossamer Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Eversept Partners, Llc | 2024-09-30 | 5 M | |
| Hillhouse Capital Advisors, Ltd. | 2024-09-30 | 5 M | |
| Monaco Asset Management | 2024-09-30 | 3.9 M | |
| Deutsche Bank Ag | 2024-06-30 | 3.8 M | |
| Opaleye Management Inc | 2024-09-30 | 3.7 M | |
| Junked Platinum Investment Management Ltd | 2024-09-30 | 3.5 M | |
| Marshall Wace Asset Management Ltd | 2024-09-30 | 3.5 M | |
| Ci Private Wealth Llc | 2024-09-30 | 3.4 M | |
| Rock Springs Capital Management Lp | 2024-09-30 | 3.3 M | |
| Nea Management Company, Llc | 2024-09-30 | 18.1 M | |
| Vanguard Group Inc | 2024-09-30 | 11.8 M |
Gossamer Bio Historical Income Statement
Gossamer Stock Against Markets
Gossamer Bio Corporate Management
| Colin Rowlings | Senior CMC | Profile | |
| Robert Smith | Chief Officer | Profile | |
| Matt Cravets | Senior Biometrics | Profile | |
| Jeff Boerneke | General Secretary | Profile | |
| Richard MD | Chief Officer | Profile | |
| Mario Orlando | Senior Planning | Profile |
Additional Tools for Gossamer Stock Analysis
When running Gossamer Bio's price analysis, check to measure Gossamer Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gossamer Bio is operating at the current time. Most of Gossamer Bio's value examination focuses on studying past and present price action to predict the probability of Gossamer Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gossamer Bio's price. Additionally, you may evaluate how the addition of Gossamer Bio to your portfolios can decrease your overall portfolio volatility.